1-3 of 3 results for subject:Streptococcus
Librarians' tools
- Search time
- 0.167 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Streptococcus
- We searched for
- subject_t:Streptococcus OR subject_t:"Strep A" OR subject_t:"Streptococcal infections" OR subject_ses:368447
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the results of the GBS3 trial can be acted upon (a) quickly and (b) effectively.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the results of the GBS3 trial can be acted upon (a) quickly and (b) effectively.
Recruitment to the GBS3 trial ended in May 2024. The researchers are analysing the data, and a report is expected in Summer 2025. The UK National Screening Committee Secretariat is in close and regular contact with the researchers. The committee will review its recommendation, considering the evidence from the trial, once the report is available.
As part of this, the UK National Screening Committee will engage with stakeholders, in line with its usual processes.
To ask the Secretary of State for Health and Social Care, if he will meet with Group B Strep Support to discuss the importance of (a) early and (b)consistent diagnosis of Group B Streptococcus.
To ask the Secretary of State for Health and Social Care, if he will meet with Group B Strep Support to discuss the importance of (a) early and (b)consistent diagnosis of Group B Streptococcus.
Recruitment to the GBS3 trial ended in May 2024. The researchers are analysing the data, and a report is expected in Summer 2025. The UK National Screening Committee Secretariat is in close and regular contact with the researchers. The committee will review its recommendation, considering the evidence from the trial, once the report is available.
As part of this, the UK National Screening Committee will engage with stakeholders, in line with its usual processes.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the development of a (a) safe and (b) effective Group B Streptococcus vaccine.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the development of a (a) safe and (b) effective Group B Streptococcus vaccine.
The UK Health Security Agency’s Vaccine Development and Evaluation Centre (VDEC) has been supporting the creation of a safe and effective maternal vaccine for Group B Streptococcus (GBS).
A maternal vaccine for GBS, which protects infants from both the early and late onset of the disease, will have a positive impact on infant mortality and morbidity. It will also lead to a sharp reduction in the use of antibiotics in neonatal units worldwide. By focusing on effectiveness, through advanced immune response evaluations, these efforts are accelerating the development of a reliable GBS vaccine that can protect vulnerable populations worldwide. Further information on how VDEC is supporting a GBS vaccine to prevent newborn deaths is available at the following link: